Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivacaftor pharmacokinetic interaction study with CYP3A4 inhibitors in cystic fibrosis and healthy adults
NL-OMON46971Active, not recruiting
- Sponsor
- HagaZiekenhuis
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ivacaftor, azithromycin, clarithromycin and ritonavir in cystic fibrosis (CF) (2 arms), sponsored by HagaZiekenhuis. Primary endpoint: Ratio of ivacaftor AUC with inhibitor versus control. Started Nov 2018; status: active, not recruiting.
02
Drugs
ivacaftorazithromycinclarithromycinritonavir
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON46971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46971.